Category Archives: Client News

Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan

RA’ANANA, Israel, and NEW YORK, July 19, 2017 — UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it will receive a … Continue reading


Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101

NEW YORK, July 17, 2017 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Columbia University (“Columbia”) has filed a provisional patent application with the U.S. … Continue reading


Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics

Robyn Hunter to assume role of Fortress Biotech’s Chief Financial Officer NEW YORK, July 03, 2017 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, announced that Lucy Lu, … Continue reading


Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock

NEW YORK, June 26, 2017  — Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (FBIO) company, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at an initial public offering price of $6.00 per … Continue reading


TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress

NEW YORK, June 26, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), recapped clinical data from two triple combination therapy trials using TGR-1202 (umbralisib), the Company’s oral, next generation PI3K delta inhibitor and TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, as the backbone of … Continue reading


TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology

MS patients treated with TG-1101 exhibited median B-cell depletion of 99% at week 4 TG-1101 was well tolerated with no grade 3/4 adverse events reported, with median time on study of 5 months NEW YORK, June 26, 2017  — TG Therapeutics, Inc. (NASDAQ:TGTX) recapped … Continue reading


Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

NEW YORK, June 26, 2017  — Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a Fortress Biotech (FBIO) company focused on the acquisition, development and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers, today announced that its common … Continue reading


Tonix Pharmaceuticals to Present at the 2017 BIO International Convention

NEW YORK, June 16, 2017  — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at the 2017 BIO International Convention being held June … Continue reading


TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma

GENUINE Phase 3 trial met its primary endpoint with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by > 70% over ibrutinib alone in patients with high-risk CLL Triple combination of TG-1101, TGR-1202 and ibrutinib produced 100% ORR (19 … Continue reading


TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress

NEW YORK, June 13, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of presentations featuring TG-1101 and TGR-1202 at the upcoming 14th International Conference on Malignant Lymphoma (ICML), being held June 14 – 17, 2017, in Lugano, Switzerland and the upcoming 22nd European Hematology Association Annual Congress (EHA), … Continue reading


TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma

Three abstracts have been selected for oral presentation, including the positive results from the GENUINE Phase 3 study, and one for poster presentation NEW YORK, June 08, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that clinical abstracts featuring TG-1101 and TGR-1202 have been … Continue reading


TG Therapeutics, Inc. to Present at the 2017 Jefferies Global Healthcare Conference

Presentation Scheduled for Thursday, June 8, 2017 at 2:00pm ET NEW YORK, June 06, 2017  — TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at the 2017 Jefferies Global Healthcare Conference, being held at The … Continue reading


TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology

Study met its primary endpoint with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by > 70% over ibrutinib alone TG-1101 plus ibrutinib achieved 78% ORR, with 7% Complete Responses (CR), compared to 45% ORR with 0% CR’s for … Continue reading


Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies

Three new licenses to expand Mustang’s CAR T pipeline into prostate cancer and multiple myeloma NEW YORK, June 05, 2017 — Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, … Continue reading


TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation NEW YORK, June 02, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX) today recapped the schedule of presentations featuring TG-1101 and TGR-1202 at the upcoming 53rd Annual Meeting of the American Society of … Continue reading


Checkpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

NEW YORK, June 01, 2017 — Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a Fortress Biotech (FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company update at the Jefferies 2017 Global Healthcare … Continue reading


Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study

Highlights of these Important Findings from AtEase Presented in Pipeline Presentation at the 2017 American Society of Clinical Psychopharmacology Annual Meeting NEW YORK, May 30, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical … Continue reading


Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

Important Retrospective Analyses from Phase 2 Study of US FDA-Designated Breakthrough Therapy TNX-102 SL in PTSD will be Highlighted NEW YORK, May 24, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to … Continue reading


Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD

Additional Important Findings Presented in Poster Session at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry NEW YORK, May 22, 2017 — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to … Continue reading


Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol

NEW YORK, May 19, 2017 — Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (FBIO) Company, today announced that Notice of Allowance has now been received from the U.S. Patent and Trademark Office (USPTO) for a new patent application (U.S. Application … Continue reading